Evalupro 3.75 mg Combipack Injection 1's

Evalupro 3.75 mg Combipack Injection 1's belongs to the class of synthetic hormones used in the treatment of prostate cancer in men, endometriosis, and hormone-responsive breast cancer in women. Also, Evalupro 3.75 mg Combipack Injection 1's is used to treat premature puberty in children. Prostate cancer is cancer of the prostate gland (a small gland under the bladder that produces semen) found only in men. The symptoms include difficulty in urination, pain, numbness, or sexual problems.

Evalupro 3.75 mg Combipack Injection 1's contains Leuprorelin, a synthetic hormone that works similarly to the natural hormone, gonadotropin-releasing hormone (GnRH), by acting on the pituitary gland and decreasing the levels of testosterone in men and estrogen in women. Thereby, Evalupro 3.75 mg Combipack Injection 1's is used in the treatment of prostate cancer by inhibiting the growth of the tumor or causing it to shrink.  

Use Evalupro 3.75 mg Combipack Injection 1's as prescribed by your doctor. You are advised to take Evalupro 3.75 mg Combipack Injection 1's for as long as your doctor has prescribed it for you based on your medical condition. In some cases, you may experience pain, redness, swelling, or skin hardening at the injection site, muscle weakness, bone pain, inability to have an erection, breast tenderness, headache, vaginal dryness, changes in breast size, acne, or mood swings. Most of these side effects of Evalupro 3.75 mg Combipack Injection 1's do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor.

If you are allergic to Evalupro 3.75 mg Combipack Injection 1's or any other medicines, please tell your doctor. Evalupro 3.75 mg Combipack Injection 1's is contraindicated in pregnant and breastfeeding women. It is advised to use effective contraceptive measures to avoid pregnancy while taking Evalupro 3.75 mg Combipack Injection 1's as it may cause birth defects. Evalupro 3.75 mg Combipack Injection 1's should be used with caution in children. You are recommended to avoid or limit consumption of alcohol with Evalupro 3.75 mg Combipack Injection 1's as it may increase the risk of bone density loss. Drive only if you are alert as Evalupro 3.75 mg Combipack Injection 1's may cause dizziness, drowsiness, or vision disturbances.

Evalupro 3.75 mg Combipack Injection 1's is used in the treatment of prostate cancer, breast cancer, endometriosis, and premature puberty. The detailed uses of Evalupro 3.75 mg Combipack Injection 1's are as follows:

• Treats Prostate Cancer in Men: Evalupro 3.75 mg Combipack Injection 1's reduces testosterone levels in men, which helps slow down or stop the growth of cancer cells in the prostate gland.
• Treats Hormone-responsive Breast Cancer in Women: Evalupro 3.75 mg Combipack Injection 1's decreases oestrogen levels, which helps slow down or stop the growth of hormone receptor-positive breast cancer cells in premenopausal women.
• Manages Endometriosis in Women: By lowering oestrogen levels, Evalupro 3.75 mg Combipack Injection 1's helps shrink the endometrial tissues outside the uterus (womb).
• Delays Premature Puberty in Children: Evalupro 3.75 mg Combipack Injection 1's delays the onset of puberty in children by suppressing the early release of sex hormones such as testosterone and oestrogen.

• Follow your doctor's instructions on the dosage and timing of this medication to ensure safety.
• Evalupro 3.75 mg Combipack Injection 1's will be administered by the doctor or healthcare professional.
• Do not self-administer.

Evalupro 3.75 mg Combipack Injection 1's contains Leuprorelin which works similarly to the natural hormone, gonadotropin-releasing hormone (GnRH), by acting on the pituitary gland and decreasing the levels of testosterone in men and oestrogen in women. Thereby, Evalupro 3.75 mg Combipack Injection 1's is used in the treatment of prostate cancer by inhibiting the growth of the tumour or causing it to shrink.  Also, Evalupro 3.75 mg Combipack Injection 1's is used to treat hormone-responsive breast cancer in pre and postmenopausal women. By reducing testosterone and oestrogen levels, Evalupro 3.75 mg Combipack Injection 1's delays the onset of puberty in children.

If you are allergic to Evalupro 3.75 mg Combipack Injection 1's or any other medicines, please tell your doctor. Evalupro 3.75 mg Combipack Injection 1's is contraindicated in pregnant and breastfeeding women. It is advised to use effective non-hormonal contraceptives such as condoms to avoid pregnancy while taking Evalupro 3.75 mg Combipack Injection 1's as it may cause birth defects. Evalupro 3.75 mg Combipack Injection 1's should be used with caution in children. You are advised to quit smoking as it may increase the risk of prostate cancer. You are recommended to avoid or limit consumption of alcohol with Evalupro 3.75 mg Combipack Injection 1's as it may increase the risk of bone density loss. Drive only if you are alert as Evalupro 3.75 mg Combipack Injection 1's may cause dizziness, drowsiness or vision disturbances.